Pretreatment lymphocyte-monocyte ratio as a potential prognostic factor in a cohort of patients with upper tract urothelial carcinoma

Journal of Clinical Pathology

Volumn 68, Issue 5, 2015, Pages 351-355

  Hutterer, Georg C ^a   Sobolev, N ^a   Ehrlich, Georg C ^a   Gutschi, Thomas ^a   Stojakovic, Tatjana ^a   Mannweiler, Sebastian ^a   Pummer, Karl ^a   Zigeuner, Richard ^a   Pichler, Martin ^a,b   Dalpiaz, Orietta ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BLOOD CELL RATIO; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; LYMPHOCYTE MONOCYTE RATIO; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; AREA UNDER THE CURVE; AUSTRIA; BLOOD; CARCINOMA; CHI SQUARE DISTRIBUTION; KAPLAN MEIER METHOD; LYMPHOCYTE; LYMPHOCYTE COUNT; MIDDLE AGED; MONOCYTE; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; TIME; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; AUSTRIA; CARCINOMA; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84928164779     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2014-202658     Document Type: Article

References (26)

1. Rouprêt M, Babjuk M, Compérat E, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 2013;63:1059-71.
2. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41.
3. Fajkovic H, Cha EK, Xylinas E, et al. Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. World J Urol 2013;31:5-11.
4. Drouin SJ, Yates DR, Hupertan V, et al. A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting. World J Urol 2013;31:109-16.
5. Rouprêt M, Hupertan V, Seisen T, et al. French national database on upper tract tumors; upper tract urothelial carcinoma collaboration. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 2013;189:1662-9.
6. Zigeuner R, Shariat SF, Margulis V, et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 2010;57:575-81.
7. Seitz C, Gupta A, Shariat SF, et al. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. J Urol 2010;184:1895-900.
8. Margulis V, Youssef RF, Karakiewicz PI, et al. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol 2010;184:453-8.
9. Roxburgh CS, Crozier JE, Maxwell F, et al. Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. Br J Cancer 2009;100:701-6.
10. Pichler M, Dalpiaz O, Ehrlich GC, et al. Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. J Urol 2014;191:920-5.
11. Pichler M, Hutterer GC, Stojakovic T, et al. High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients. Br J Cancer 2013;109:1123-9.
12. Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 2013;108:901-7.
13. Dalpiaz O, Pichler M, Mannweiler S, et al. Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Br J Cancer 2014;110:2531-6.
14. Stotz M, Pichler M, Absenger G, et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer 2014;110:435-40.
15. Szkandera J, Gerger A, Liegl-Atzwanger B, et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 2014;135:362-70.
16. Hutterer GC, Stoeckigt C, Stojakovic T, et al. Low pre-operative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in non-metastatic clear cell renal cell carcinoma. Urol Oncol 2014;32:1041-8, in press.
17. Tanaka N, Kikuchi E, Matsumoto K, et al. Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma. BJU Int 2013;111:857-64.
18. Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. Urological tumours. Renal Pelvis and Ureter. 7th revised edition. Wiley-Blackwell, 2009:258-61. http://www.uicc.org/tnm/
19. Martens-Uzunova ES, Böttcher R, Croce CM, et al. Long noncoding RNA in Prostate, Bladder, and Kidney cancer. Eur Urol 2014;65:1140-51.
20. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
21. Zikos TA, Donnenberg AD, Landreneau RJ, et al. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in non-small cell lung cancer. Cancer Immunol Immunother 2011;60:819-27.
22. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol 2013;35:585-600.
23. Hutterer GC, Pichler M, Chromecki TF, et al. Tumour-associated macrophages might represent a favourable prognostic indicator in patients with papillary renal cell carcinoma. Histopathology 2013;63:309-15.
24. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254-65.
25. Partecke LI, Günther C, Hagemann S, et al. Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: a quid pro quo in pancreatic cancer. Pancreatology 2013;13:508-16.
26. Bleeker SE, Moll HA, Steyerberg EW, et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 2003;56:826-32.